Once a quality lead compound with good physicochemical properties has been validated, Array scientists, working as an integrated team with our collaborators, assess and balance potency, selectivity, ADMET, PK/PD as well as other parameters of the compounds considered for candidate nomination.
Typically two or three structurally distinct lead molecules are optimized in parallel to enhance the chances of inventing a quality clinical candidate. Furthermore, Array tends to push advanced leads deep into the screening cascade to uncover potential problems earlier instead of later.
In addition, Array keeps a keen eye on competitor programs and candidates. In certain cases, benchmarking our leads vs. competitor compounds has allowed us to engender competitive advantages that, ultimately, result in best-in-class attributes.